Product Details
| Product Name:
BVT948 |
CAS No.:
39674-97-0 |
| Purity:
98.70% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | BVT948 |
| Description | BVT948 is a protein tyrosine phosphatase (PTP) inhibitor that also inhibits lysine methyltransferase SETD8 (KMT5A) and various cytochrome P450 (P450) isoforms. |
| In vitro | BVT948 exhibits dose-dependent inhibition of TPA-induced MMP-9 up-regulation, without affecting MAPK phosphorylation caused by TPA. It reduces TPA-induced cell invasion by 50%. Interestingly, BVT948 does not significantly alter cell viability in MCF-7 cells at concentrations of 0.5, 1, or 5 μM over 24 hours. Furthermore, BVT948 is a potent inhibitor of protein tyrosine phosphatases (PTP) and P450 activities, demonstrating its ability to selectively suppress H4 lysine 20 (H4K20me1) methylation at doses below 5 μM within 24 hours. Additionally, it enhances the insulin signal's strength without affecting its duration and induces cell-cycle-arrest phenotypes reminiscent of those observed with SETD8 knockdown via RNAi. BVT948 also effectively inhibits TPA-induced NF-κB binding activity but not AP-1 binding activity, showcasing its selective inhibitory properties on specific molecular targets. |
| In vivo | Compare with vehicle-treated controls, BVT948 (BVT.948, 3 μmol/kg) significantly enhances glucose clearance from the blood stream in response to insulin[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (414.52 mM), Sonication is recommended.
|
| Keywords | Cytochrome P450 | Histone Methyltransferase | BVT948 | Inhibitor | BVT 948 | Phosphatase | BVT-948 | CYPs | inhibit |
| Inhibitors Related | Tebuconazole | β-Glycerophosphate disodium salt pentahydrate | Apigenin | Fenofibrate | EPZ015666 | 1-Aminobenzotriazole | Tartaric acid disodium dihydrate | Cyclosporine | Stearic acid | Naringin | Naringenin | Tauroursodeoxycholate |
| Related Compound Libraries | Glycometabolism Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Metabolism Disease Compound Library | Phosphatase Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:33089-61-1
$55.00 / 500mg
-
CAS:781658-23-9
$30.00 / 5mg
-
CAS:2098884-52-5
$197.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$41.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States